Formic Acid

Formic Acid

SCHEMBL4666146

Cc1ccc(S(=O)(=O)Nc2ccc(Nc3cc(-c4ccc5c(ccn5CCCN5CCN(C)CC5)c4)ncn3)cc2)cc1.O=CO

nearest known ligand 0.39

Full drug profile on Sugi Atlas →

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
HTR6 P50406 2/20 0.38
PAX8 Q06710 1/20 0.38
POLB P06746 1/20 0.37
RAB9A P51151 1/20 0.37
GSK3B P49841 1/20 0.37
KIT P10721 2/20 0.36
KDM4E B2RXH2 2/20 0.36
GAA P10253 2/20 0.36
MAPT P10636 2/20 0.36
BPTF Q12830 2/20 0.36
ALDH1A1 P00352 2/20 0.35
USP2 O75604 1/20 0.34
ALOX12 P18054 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.34
HSD17B10 Q99714 1/20 0.34
EGFR P00533 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Formic Acid SCHEMBL4664334 0.96 RAB9A (0.39) HTR6PAX8POLBRAB9AGSK3B
Formic Acid SCHEMBL4666096 0.95 PAX8 (0.43) HTR6PAX8RAB9AGSK3BKIT
Formic Acid SCHEMBL4666206 0.93 ABL1 (0.41) HTR6GSK3BKITMAPT
Formic Acid SCHEMBL4667472 0.91 PAX8 (0.44) HTR6PAX8RAB9AGSK3BKIT
Formic Acid SCHEMBL4667501 0.89 AXL (0.41) HTR6RAB9AGSK3BKITEGFR
Formic Acid SCHEMBL4664367 0.88 ABL1 (0.41) HTR6GSK3BKITMAPTALDH1A1
Formic Acid SCHEMBL4665737 0.88 LMNA (0.42) HTR6GSK3BKITSMN1; SMN2HSD17B10
Formic Acid SCHEMBL4666133 0.88 AXL (0.39) HTR6BPTFUSP2EGFR
Formic Acid SCHEMBL4665754 0.87 AXL (0.39) HTR6BPTF
Formic Acid SCHEMBL4666208 0.86 HTR6 (0.46) HTR6KDM4EGAAMAPTBPTF

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080242681-A1 N-4-(6-(Hetero)Aryl-Pyrimidin-4-Ylaminophenyl)-Benzenesulfonamides as Kinase Inhibitors ALTANA PHARMA AG (DE) 2008-10-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080242681-A1 N-4-(6-(Hetero)Aryl-Pyrimidin-4-Ylaminophenyl)-Benzenesulfonamides as Kinase Inhibitors MAP3K19, MAP3K6, MAP3K20 HTR6 826/4885PAX8 3610/4885POLB 2689/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.